Aperio Group LLC lifted its holdings in shares of Cantel Medical Corp. (NYSE:CMD) by 8.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 13,894 shares of the company’s stock after purchasing an additional 1,075 shares during the quarter. Aperio Group LLC’s holdings in Cantel Medical Corp. were worth $1,308,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Cantel Medical Corp. during the second quarter worth about $376,271,000. Vanguard Group Inc. acquired a new stake in shares of Cantel Medical Corp. during the second quarter worth about $246,860,000. Neuberger Berman Group LLC acquired a new stake in shares of Cantel Medical Corp. during the second quarter worth about $96,236,000. Dimensional Fund Advisors LP acquired a new stake in shares of Cantel Medical Corp. during the second quarter worth about $75,756,000. Finally, Wells Fargo & Company MN acquired a new stake in shares of Cantel Medical Corp. during the second quarter worth about $75,715,000. 85.16% of the stock is currently owned by institutional investors and hedge funds.
Shares of Cantel Medical Corp. (NYSE CMD) opened at $103.65 on Friday. The firm has a market cap of $4,340.00, a P/E ratio of 48.42 and a beta of 1.23. Cantel Medical Corp. has a 1-year low of $69.21 and a 1-year high of $104.28. The company has a quick ratio of 1.49, a current ratio of 2.41 and a debt-to-equity ratio of 0.24.
Cantel Medical Corp. (NYSE:CMD) last issued its earnings results on Thursday, September 28th. The company reported $0.54 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.02. The firm had revenue of $205.50 million for the quarter, compared to analysts’ expectations of $200.32 million. Cantel Medical Corp. had a net margin of 9.27% and a return on equity of 17.60%. The business’s revenue for the quarter was up 14.8% on a year-over-year basis. equities analysts forecast that Cantel Medical Corp. will post 2.34 EPS for the current year.
The company also recently announced a Semi-Annual dividend, which will be paid on Wednesday, January 31st. Investors of record on Wednesday, January 17th will be issued a $0.085 dividend. This is a boost from Cantel Medical Corp.’s previous Semi-Annual dividend of $0.07. The ex-dividend date is Tuesday, January 16th. This represents a yield of 0.17%. Cantel Medical Corp.’s dividend payout ratio (DPR) is 8.19%.
TRADEMARK VIOLATION NOTICE: This article was first posted by Week Herald and is the property of of Week Herald. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://weekherald.com/2017/11/18/aperio-group-llc-raises-stake-in-cantel-medical-corp-cmd.html.
CMD has been the topic of several research reports. Zacks Investment Research raised shares of Cantel Medical Corp. from a “hold” rating to a “buy” rating and set a $83.00 price target on the stock in a research report on Tuesday, August 1st. Needham & Company LLC reissued a “hold” rating on shares of Cantel Medical Corp. in a research report on Friday, September 1st. Finally, Sidoti raised shares of Cantel Medical Corp. from a “neutral” rating to a “buy” rating and set a $92.00 price target on the stock in a research report on Wednesday, August 2nd. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $91.67.
In related news, Chairman Charles M. Diker sold 20,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $99.15, for a total value of $2,032,575.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director George L. Fotiades sold 6,000 shares of the firm’s stock in a transaction that occurred on Friday, October 13th. The shares were sold at an average price of $95.23, for a total transaction of $571,380.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 36,368 shares of company stock worth $3,576,028. 14.90% of the stock is owned by corporate insiders.
Cantel Medical Corp. Company Profile
Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.